Skip to content
10-Q

Quarterly Report

Indivior Pharmaceuticals, Inc. INDV

0001628280-26-028850

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 1, 2026 121.92M sh
Shares Diluted Q1 2026 · Mar 31, 2026 129M sh
Shares Diluted Q1 2026 · Mar 31, 2025 125M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $126M
Stock Repurchased Q1 2026 · Mar 31, 2025 $11M
Capex Q1 2026 · Mar 31, 2026 $20M
Capex Q1 2026 · Mar 31, 2025 $5M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $75M
Long Term Debt Q1 2026 · Mar 31, 2026 $486M
Long Term Debt Q1 2026 · Dec 31, 2025 $290M
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Short Term Debt Q1 2026 · Dec 31, 2025 $29M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $175M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $195M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$144M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$98M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$285M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$337M
Current Liabilities Q1 2026 · Mar 31, 2026 $779M
Current Liabilities Q1 2026 · Dec 31, 2025 $914M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.34B
Total Liabilities Q1 2026 · Dec 31, 2025 $1.3B
Current Assets Q1 2026 · Mar 31, 2026 $667M
Current Assets Q1 2026 · Dec 31, 2025 $652M
Total Assets Q1 2026 · Mar 31, 2026 $1.2B
Total Assets Q1 2026 · Dec 31, 2025 $1.2B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.69
Eps Diluted Q1 2026 · Mar 31, 2025 $0.38
Eps Basic Q1 2026 · Mar 31, 2026 $0.71
Eps Basic Q1 2026 · Mar 31, 2025 $0.38
Sga Expense Q1 2026 · Mar 31, 2026 $124M
Sga Expense restated Q1 2026 · Mar 31, 2025 $133M
Net Income Q1 2026 · Mar 31, 2026 $89M
Net Income Q1 2026 · Mar 31, 2025 $47M
Operating Income Q1 2026 · Mar 31, 2026 $137M
Operating Income Q1 2026 · Mar 31, 2025 $66M
Gross Profit Q1 2026 · Mar 31, 2026 $277M
Gross Profit Q1 2026 · Mar 31, 2025 $221M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $40M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $44M
Revenue Q1 2026 · Mar 31, 2026 $317M
Revenue Q1 2026 · Mar 31, 2025 $266M